Hemostemix Inc. (CVE:HEM – Get Free Report) fell 22.9% during trading on Thursday . The company traded as low as C$0.18 and last traded at C$0.19. 504,239 shares were traded during trading, a decline of 5% from the average session volume of 530,580 shares. The stock had previously closed at C$0.24.
Hemostemix Price Performance
The stock has a fifty day moving average of C$0.19 and a two-hundred day moving average of C$0.11. The company has a current ratio of 0.04, a quick ratio of 0.48 and a debt-to-equity ratio of -55.07. The stock has a market capitalization of C$28.42 million, a price-to-earnings ratio of -5.69 and a beta of 0.20.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Recommended Stories
- Five stocks we like better than Hemostemix
- What Does Downgrade Mean in Investing?
- Roblox’s Big Dip: A Chance to Get in on the Vaunted Gaming Stock?
- How to buy stock: A step-by-step guide for beginners
- 3 Dividend ETFs to Capitalize on the Slide in Chip Stocks
- What Are Treasury Bonds?
- Is Chevron Stock Primed for Growth After Profit-Boosting News?
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
